CD8A and myeloid sarcoma: They raise regulatory CD8 + T cells from subnormal to supranormal levels over 18 months (12), deplete a small population of cytolytic CD20dim, CD8+ T cells that recognize myelin basic protein (13) and deplete CD20dim CD4 and CD8 cells that secrete pro-inflammatory cytokines and predict MS disease activity (14, 15), and reduce pro-inflammatory IL-12 and increase anti-inflammatory IL-10 production by monocytes (8).